-+ 0.00%
-+ 0.00%
-+ 0.00%

Wells Fargo Maintains Overweight on ORIC Pharmaceuticals, Lowers Price Target to $23

Benzinga·11/18/2026 14:36:28
Listen to the news
Wells Fargo analyst Derek Archila maintains ORIC Pharmaceuticals (NASDAQ:ORIC) with a Overweight and lowers the price target from $25 to $23.